newsfilter
← Latest News
Business Wire·

Rallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates

– RLYB116 Confirmatory PK/PD Study Data Expected in 4Q 2025 – – Generated $20 Million from Sale of Interest in REV102 – – Cash Runway Extended through 2027 – Rallybio Corporation (NASDAQ:RLYB), a clinical-stage